Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel Geller
Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, USA
Objective: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD).
Methods: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or adolescent ADHD.
Results: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short- and longer-term efficacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine’s therapeutic potential for other psychiatric conditions. Short- and longer-term safety and tolerability continue to be reported.
Conclusions: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine’s evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity.
Keywords: ADHD, atomoxetine, pediatric
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Multifunction hexagonal liquid-crystal containing modified surface TiO2 nanoparticles and terpinen-4-ol for controlled release
Manaia EB, Kaminski RCK, Oliveira AG, Corrêa MA, Chiavacci LA
Published Date: 22 January 2015
Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups
Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A
Published Date: 21 January 2015
Chiriac A, Brzezinski P, Foia L, Marincu I
Published Date: 14 January 2015
Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer
Zhao XJ, Chen Q, Liu W, Li YS, Tang HB, Liu XH, Yang XL
Published Date: 30 December 2014
Photothermal cancer therapy using graphitic carbon–coated magnetic particles prepared by one-pot synthesis
Lee HJ, Sanetuntikul J, Choi ES, Lee BR, Kim JH, Kim E, Shanmugam S
Published Date: 30 December 2014
Thomsen RW, Sørensen HT
Published Date: 18 December 2014
Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification
Lindstrom RL, Loden JC, Walters TR, Dunn SH, Whitaker JS, Kim T, Demopulos GA, Tjia K
Published Date: 5 September 2014
Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response [Corrigendum]
Tomita T, Norio YF, Sato Y, Nakagami T, Tsuchimine S, Kaneda A, Kaneko S
Published Date: 5 June 2014
Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity
Published Date: 6 July 2012
Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery
Stephen Smith, Douglas Lorenz, James Peace, et al.
Published Date: 30 August 2010